Amgen/Novartis CGRP Inhibitor Migraine Data Underwhelm Ahead Of Phase III Apex
Amgen Inc. and Novartis AG are busy shoring up the case for their CGRP inhibitor erenumab – which is in a race with three others to be the first on to the migraine market. Positive topline Phase II data with erenumab has been reported but analysts suggest they may not be as strong as those from its competitors. The four CGRP inhibitors are all in Phase III with late-stage data expected this year.
You may also be interested in...
In a very strong second-quarter earnings report, Amgen reports just $27m in worldwide sales for cholesterol-busting PCSK9 inhibitor Repatha, as reimbursement continues to present a big hurdle.
Teva Pharmaceutical Industries Ltd. has signed an exclusive licensing agreement for Heptares Therapeutics' small-molecule calcitonin gene-related peptide (CGRP) antagonist program for the treatment of migraine. A wave of biologicals targeting the CGRP pathway are approaching late-stage development, but Heptares CEO Malcolm Weir believes that small molecule CGRP antagonists "present the opportunity for delivery using routes that are not available to biologics, such as oral or intra-nasal, and for patients with different needs, such as in acute therapy," he told Scrip.
Amgen traded certain ex-US rights to its Phase III calcitonin gene-related peptide (CGRP) inhibitor for migraine headaches to acquire shared global rights to Novartis's early-stage candidate for Alzheimer's disease, raising an important question: Who is getting the better deal?